Participated · Series A · May 2026

cAMPfield Therapeutics is a newly formed biotechnology company backed by Mountainfield Venture Partners and other life-science investors to advance licensed development-stage therapeutic candidates. Its CEO, Bill Gerhart, has more than two decades of experience in pulmonary, fibrosis, and inflammatory diseases and a track record of leading biotech exits. Other senior leaders include CTO Patricia Turney and global head of regulatory affairs Rita Shah. Public filings and reporting link cAMPfield to vTv Therapeutics' HPP737, a PDE4 inhibitor that has been studied in China for psoriasis, COPD, atopic dermatitis, and idiopathic pulmonary fibrosis, including an ongoing Phase 3 psoriasis trial there. The company's explicit pipeline needs are not detailed in the coverage, nor are financial metrics beyond the $180 million Series A. cAMPfield appears positioned to progress licensed candidates through clinical development with capital from its recent financing.

Participated · Series A · Jan 2026

AirNexis Therapeutics is focused on creating new treatments for pulmonary diseases, with an initial emphasis on chronic obstructive pulmonary disease. Its lead asset, AN01, is a dual PDE3/4 inhibitor that simultaneously drives bronchodilation and dampens inflammatory pathways, offering a synergistic mechanism of action for COPD patients. The molecule, currently in Phase 2 development, was recently in-licensed from Haisco Pharmaceutical Group, giving AirNexis worldwide rights outside China. Led by CEO Maria Fardis, the company plans to advance AN01 through global clinical trials and pursue additional indications within pulmonary medicine. The $200 million Series A financing provides the capital required to accelerate clinical development, expand regulatory activities, and build out manufacturing capabilities. No commercial revenue has yet been reported, reflecting the company’s clinical-stage status, and financial resources now largely consist of the new equity infusion.

Led · Series A · Jan 2026

Ventaris Surgical is a privately held med-tech firm focused on improving kidney stone surgery through a novel ureteroscopic system that minimizes friction in the procedure and helps surgeons attain consistent, complete stone clearance. The company asserts that current instruments make it difficult to reliably remove all stones because of anatomical variation, stone burden, workflow constraints, and surgeon fatigue. By redesigning the toolset, Ventaris intends to boost surgical outcomes while easing surgeon workload. Headquartered in San Carlos, California, the startup is still in the clinical development stage and has not disclosed commercial revenues or user metrics. It plans to use newly raised capital to advance clinical studies and achieve key regulatory and commercial milestones. Board expansion accompanies the financing, adding Varun Gupta (Longitude Capital) and Justin Klein (Vensana Capital) alongside independent director Amir Abolfathi.

Participated · Series C · Oct 2025

Veradermics is a late clinical-stage, dermatologist-founded biopharmaceutical company focused on first-in-class treatments for common dermatologic conditions. Its lead candidate, VDPHL01, is an extended-release, non-hormonal oral minoxidil tablet positioned to become the first FDA-approved oral therapy for pattern hair loss in both women and men. VDPHL01 is currently being evaluated in three Phase 3 trials after encouraging Phase 2 male data showed average hair count increases of 37.5 hairs/cm² at two months and 47.3 hairs/cm² at four months, with 90.5 % of participants reporting improved coverage and no serious adverse events. The formulation aims to sustain minoxidil exposure to follicles while avoiding cardiac risk–related concentration spikes seen in immediate-release versions. Proceeds from the recent financing will fund completion of Phase 3 registrational trials and a planned New Drug Application submission to the FDA. Beyond VDPHL01, Veradermics is building a pipeline of differentiated dermatology products that combine proven mechanisms with innovative delivery technologies to enhance efficacy, safety, and patient convenience.

Participated · Series C · May 2025

Cohere Health builds AI-powered clinical intelligence and prior authorization solutions for health plans and risk-bearing providers. Its Cohere Unify platform personalizes provider workflows, modernizes utilization management, and enables collaboration between plans and providers using real-time performance data. The company says its AI auto-approves up to 90% of requests and currently processes more than 12 million prior authorization requests annually for over 600,000 providers. The new funding will accelerate scaling the Cohere Unify platform, expand into new clinical use cases, and deepen investment in its AI-powered product portfolio. Cohere emphasizes a clinician-led, responsible AI-first approach to maintain clinical expertise, transparency, and accountability in automation. Following this round the company has raised $200 million to date and has been recognized by Gartner, LinkedIn, and KLAS for its contributions to clinical intelligence and healthcare automation. Cohere Health provides intelligent prior authorization by aligning physicians and health plans on evidence-based care paths across the patient’s entire care journey. Its platform automates prior authorization processes to reduce administrative expenses and improve patient outcomes. The company serves five health plans and processes 5.5 million intelligent prior authorizations annually for more than 15 million health plan members and 420,000 healthcare providers nationally. Cohere is led by CEO Siva Namasivayam and is based in Boston, MA. The company raised $50M in equity funding in the latest round, bringing total disclosed funding to $106M. It intends to use the funds to accelerate expansion to meet demand for its platform. Cohere Health, based in Boston, MA and led by CEO Siva Namasivayam, provides digital health plan solutions to drive collaborative care journeys. Its platform automates provider and payer preauthorization functions and generates clinical policy guidance to inform care decisions without delaying or denying care. The company uses prior authorization as a trigger to engage plans, providers and patients in episode-based care paths that merge utilization management, care management and patient engagement. Cohere works with physicians and health plans. It closed an additional $36M Series B and intends to use the funds to continue enhancement of its digital health plan solutions. Cohere Health offers an innovative technology platform that replaces legacy, siloed processes to align physicians and health plans around the entire patient care journey rather than individual service transactions. Its platform emphasizes transparent, evidence-based clinical algorithms and human-centered design to reduce administrative burden for physicians and health plans. Cohere aims to improve quality of care, lower total cost of care, and transform the patient and physician experience while facilitating the transition from fee-for-service to value-based payment arrangements. The company provides an evolutionary path that can support all payment arrangements and reduce unnecessary variation in clinical outcomes. Cohere assembled a leadership team including CEO Siva Namasivayam and Chairperson Gary Gottlieb, MD. The company announced a $10 million Series A in conjunction with its launch.